Home Visit
Upload
.png)
BCR ABL1 Mutation Analysis Test in Mumbai
50+ booked in last 3 days
No special precautions
Sample Type
Blood
Recommended for
Male, Female
Report
Within 24 Hours
Blood test at Home
NABL & CAP Accredited Labs
Accurate & Quality Test Reports
Trusted by Leading Doctors & Hospitals
BCR ABL Test Overview
BCR-ABL1 Mutation Analysis is a diagnostic test used to detect mutations in the BCR-ABL1 fusion gene in Chronic Myeloid Leukemia (CML) patients. It serves as a crucial therapy resistance marker, as specific mutations in the BCR-ABL1 kinase domain can lead to resistance to tyrosine kinase inhibitors (TKIs), the mainstay of CML treatment. By identifying these mutations, the test helps guide treatment decisions by allowing for alternative therapy selection or dose adjustments to overcome drug resistance. Regular monitoring of BCR-ABL1 mutations during treatment enables early detection of resistance and timely intervention, optimizing treatment outcomes in CML patients.
BCR ABL1 Mutation Analysis Test Price in Mumbai
Metropolis Healthcare is a leading diagnostics centre and pathology lab in India equipped with the latest state-of-the-art technologies that provides the BCR ABL1 Mutation Analysis Test with a clear pricing structure
The price of BCR ABL1 Mutation Analysis Test in Mumbai is ₹ 10,710
We are committed to deliver accurate and quality results from the best labs in India with complete transparency regarding test cost and turnaround time. No matter where you are, we strive to offer patients high-quality service that is affordable and accessible.
Frequently Asked Questions
Acts as a Therapy resistance marker in CML.
Your doctor may suggest to get test done to evaluate patients with chronic myelogenous leukemia and Philadelphia chromosome positive B-cell acute lymphoblastic leukemia receiving tyrosine kinase inhibitor (TKI) therapy, who are apparently failing treatment.
Mutations in the Bcr-Abl kinase domain may cause, or contribute to, resistance to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia patients. In chronic phase patients receiving imatinib first-line, mutation analysis is recommended only in case of failure or suboptimal response. In imatinib-resistant patients receiving an alternative TKI, mutation analysis is recommended in case of hematologic or cytogenetic failure & a positive result is an indication for therapeutic change. Some specific mutations weigh on TKI selection.
Ratings & Reviews (0)
Why Metropolis?
Metropolis has a team of 200 senior pathologists and over 2000 technicians delivering diagnostic solutions in the areas of routine, semi specialty and super specialty domains like Oncology, Neurology, Gynaecology, Nephrology and many more.
We offer a comprehensive range of 4000+ clinical laboratory tests and profiles, which are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of the disease.
WhatsApp